Published: 28 October 2020
Author(s): Giulio Cavalli, Lorenzo Dagna
Issue: January 2021
Section: Commentary

In this issue of the Journal, Di Castelnuovo and colleagues report the findings of the observational multicentre Italian CORIST Study on the use of hydroxychloroquine (HCQ) in hospitalised COVID-19 patients [1]. In this large, retrospective cohort of 3,451 COVID-19 inpatients from 33 clinical centers, the use of HCQ was associated with a significant increase in survival. Specifically, the Authors reported an in-hospital death rate of 8.9 per 1,000 person-day for patients receiving HCQ, and of 15.7 for patients not receiving HCQ.

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

randomness